• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Hemodynamic Evaluation of Nonselective -Blockers in Patients with Cirrhosis and Refractory Ascites.

作者信息

Ferrarese Alberto, Tikhonoff Valerie, Casiglia Edoardo, Angeli Paolo, Fasolato Silvano, Faggian Diego, Zanetto Alberto, Germani Giacomo, Russo Francesco Paolo, Burra Patrizia, Senzolo Marco

机构信息

Multivisceral Transplant Unit, Department of Surgery, Oncology and Gastroenterology, Padua University Hospital, Padua, Italy.

Department of Medicine, Padua University Hospital, Padua, Italy.

出版信息

Gastroenterol Res Pract. 2018 May 9;2018:4098210. doi: 10.1155/2018/4098210. eCollection 2018.

DOI:10.1155/2018/4098210
PMID:29861720
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5971311/
Abstract

BACKGROUND

Nonselective -blockers (NSBB) have been associated with increased incidence of paracentesis-induced circulatory dysfunction (PICD) and reduced survival in patients with cirrhosis and refractory ascites.

AIM

To prospectively evaluate a hemodynamic response to NSBB in cirrhotics listed for liver transplantation with refractory ascites undergoing large volume paracentesis (LVP).

METHODS

Patients with cirrhosis and refractory ascites, with an indication to start NSBB in primary prophylaxis for variceal bleeding, were enrolled. During two consecutive LVP, while being, respectively, off and on NSBB, cardiac output (CO), systemic vascular resistances (SVR), peripheral vascular resistances (PVR), and plasma renin activity (PRA) were noninvasively assessed.

RESULTS

Seventeen patients were enrolled, and 10 completed the study. Before NSBB introduction, SVR (1896 to 1348 dyn·s·cm; = 0.028) and PVR (47 to 30 mmHg·min·dl·ml; = 0.04) significantly decreased after LVP, while CO showed an increasing trend (3.9 to 4.5 l/m; = 0.06). After NSBB introduction, LVP was not associated with a significant increase in CO (3.4 to 3.8 l/m; = 0.13) nor with a significant decrease in SVR (2002 versus 1798 dyn·s·cm; = 0.1). Incidence of PICD was not increased after NSBB introduction.

CONCLUSION

The negative inotropic effect of NSBB was counterbalanced by a smaller decrease of vascular resistances after LVP, probably due to splanchnic 2-blockade. This pilot study showed that NSBB introduction may be void of detrimental hemodynamic effects after LVP in cirrhotics with refractory ascites.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3391/5971311/e371204bea2a/GRP2018-4098210.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3391/5971311/daa7bc59de6d/GRP2018-4098210.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3391/5971311/d668b10dc483/GRP2018-4098210.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3391/5971311/e371204bea2a/GRP2018-4098210.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3391/5971311/daa7bc59de6d/GRP2018-4098210.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3391/5971311/d668b10dc483/GRP2018-4098210.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3391/5971311/e371204bea2a/GRP2018-4098210.003.jpg

相似文献

1
Hemodynamic Evaluation of Nonselective -Blockers in Patients with Cirrhosis and Refractory Ascites.
Gastroenterol Res Pract. 2018 May 9;2018:4098210. doi: 10.1155/2018/4098210. eCollection 2018.
2
Predictors of large volume paracantesis induced circulatory dysfunction in patients with massive hepatic ascites.大量肝腹水患者大量腹腔穿刺放液所致循环功能障碍的预测因素
J Cardiovasc Dis Res. 2010 Jul;1(3):136-44. doi: 10.4103/0975-3583.70914.
3
Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study.β受体阻滞剂可引起肝硬化伴难治性腹水患者经皮穿刺放液后循环功能障碍:一项交叉研究。
J Hepatol. 2011 Oct;55(4):794-9. doi: 10.1016/j.jhep.2011.01.034. Epub 2011 Feb 24.
4
The impact of paracentesis flow rate in patients with liver cirrhosis on the development of paracentesis induced circulatory dysfunction.肝硬化患者腹腔穿刺引流流速对腹腔穿刺诱发循环功能障碍发生的影响
Clin Mol Hepatol. 2015 Dec;21(4):365-71. doi: 10.3350/cmh.2015.21.4.365. Epub 2015 Dec 24.
5
Non-selective β-blockers are associated with improved survival in patients with ascites listed for liver transplantation.非选择性β受体阻滞剂可改善等待肝移植患者腹水的生存率。
Gut. 2015 Jul;64(7):1111-9. doi: 10.1136/gutjnl-2013-306502. Epub 2014 Oct 3.
6
Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites.非选择性β受体阻滞剂会损害顽固性腹水肝硬化患者的整体循环稳态和肾功能。
J Hepatol. 2020 Dec;73(6):1404-1414. doi: 10.1016/j.jhep.2020.05.011. Epub 2020 May 21.
7
Clinical Implications, Evaluation, and Management of Hyponatremia in Cirrhosis.肝硬化患者低钠血症的临床意义、评估及管理
J Clin Exp Hepatol. 2022 Mar-Apr;12(2):575-594. doi: 10.1016/j.jceh.2021.09.008. Epub 2021 Sep 16.
8
Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients.非选择性β受体阻滞剂不会影响肝硬化腹水患者的死亡率:三项随机对照试验的事后分析,共纳入 1198 例患者。
Hepatology. 2016 Jun;63(6):1968-76. doi: 10.1002/hep.28352. Epub 2016 Jan 5.
9
Beta-blockers in liver cirrhosis.肝硬化中的β受体阻滞剂
Ann Gastroenterol. 2014;27(1):20-26.
10
Non-selective beta blocker use is associated with improved short-term survival in patients with cirrhosis referred for liver transplantation.非选择性β受体阻滞剂的使用与肝硬化患者在接受肝移植时的短期生存率提高有关。
BMC Gastroenterol. 2020 Jan 6;20(1):4. doi: 10.1186/s12876-019-1155-1.

引用本文的文献

1
Is carvedilol superior to propranolol in patients with cirrhosis with portal hypertension: a systematic and meta-analysis.在肝硬化门静脉高压患者中,卡维地洛是否优于普萘洛尔:一项系统评价和荟萃分析。
Drugs Context. 2025 Feb 24;14. doi: 10.7573/dic.2024-11-3. eCollection 2025.
2
β-blockers in advanced cirrhosis: More friend than enemy.β受体阻滞剂在晚期肝硬化中的应用:利大于弊。
Clin Mol Hepatol. 2021 Jul;27(3):425-436. doi: 10.3350/cmh.2020.0234. Epub 2020 Dec 3.
3
Diuretic window hypothesis in cirrhosis: Changing the point of view.肝硬化利尿剂治疗窗假说:改变观点。

本文引用的文献

1
Clinical states of cirrhosis and competing risks.肝硬化的临床状态和竞争风险。
J Hepatol. 2018 Mar;68(3):563-576. doi: 10.1016/j.jhep.2017.10.020. Epub 2017 Oct 27.
2
Beta adrenergic blockade and decompensated cirrhosis.β肾上腺素能阻断剂与失代偿性肝硬化。
J Hepatol. 2017 Apr;66(4):849-859. doi: 10.1016/j.jhep.2016.11.001. Epub 2016 Nov 15.
3
Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure.
World J Gastroenterol. 2019 Jul 14;25(26):3283-3290. doi: 10.3748/wjg.v25.i26.3283.
非选择性β受体阻滞剂治疗与降低慢加急性肝衰竭患者全身炎症反应严重程度和改善患者生存相关。
J Hepatol. 2016 Mar;64(3):574-82. doi: 10.1016/j.jhep.2015.10.018. Epub 2015 Oct 28.
4
Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments.门静脉高压病理生理基础认识的演变:范式转变如何引领成功的新治疗方法。
J Hepatol. 2015 Apr;62(1 Suppl):S121-30. doi: 10.1016/j.jhep.2015.01.003.
5
Beta-blockers in cirrhosis: therapeutic window or an aspirin for all?肝硬化中的β受体阻滞剂:治疗窗口还是适用于所有人的阿司匹林?
J Hepatol. 2014 Aug;61(2):449-50. doi: 10.1016/j.jhep.2014.03.038. Epub 2014 Apr 24.
6
Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis.非选择性β受体阻滞剂会增加肝硬化合并自发性细菌性腹膜炎患者发生肝肾综合征和死亡的风险。
Gastroenterology. 2014 Jun;146(7):1680-90.e1. doi: 10.1053/j.gastro.2014.03.005. Epub 2014 Mar 12.
7
The changing role of beta-blocker therapy in patients with cirrhosis.肝硬化患者β受体阻滞剂治疗作用的变化。
J Hepatol. 2014 Mar;60(3):643-53. doi: 10.1016/j.jhep.2013.09.016. Epub 2013 Sep 26.
8
Can non-invasive measurements aid clinical assessment of volume in patients with cirrhosis?非侵入性测量能否辅助肝硬化患者的容量临床评估?
World J Hepatol. 2013 Aug 27;5(8):433-8. doi: 10.4254/wjh.v5.i8.433.
9
Assessment of intravascular volume status and volume responsiveness in critically ill patients.危重症患者的血管内容量状态评估和容量反应性评估。
Kidney Int. 2013 Jun;83(6):1017-28. doi: 10.1038/ki.2012.424. Epub 2013 Jan 9.
10
Benefits of Beta blockade beyond bleeding prophylaxis and the role of adherence.
Am J Gastroenterol. 2012 Oct;107(10):1593. doi: 10.1038/ajg.2012.261.